The Journal of Pain
Volume 11, Issue 2 , Pages 109-118 , February 2010

The Clinical Importance of Changes in the 0 to 10 Numeric Rating Scale for Worst, Least, and Average Pain Intensity: Analyses of Data from Clinical Trials of Duloxetine in Pain Disorders

  • John T. Farrar

      Affiliations

    • Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Corresponding Author InformationAddress reprint requests to Dr John T. Farrar, University of Pennsylvania School of Medicine, 423 Guardian Drive, Room 816, Philadelphia, PA 19041.
    • ,
  • Yili L. Pritchett

      Affiliations

    • Global Pharmaceutical R&D, Abbott Laboratories, Abbot Park, Illinois
    • ,
  • Michael Robinson

      Affiliations

    • Lilly USA, LLC, Indianapolis, Indiana
    • ,
  • Apurva Prakash

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
    • ,
  • Amy Chappell

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

Received 8 December 2008 ,Revised 12 May 2009 ,Accepted 8 June 2009.

References 

  1. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974–2984
  2. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15
  3. Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum. 1995;38:1568–1580
  4. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691
  5. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138
  6. Cook DJ, Guyatt GH, Davis C, Willan A, McIlroy W. A diagnostic and therapeutic N-of-1 randomized trial. Can J Psychiatry. 1993;38:251–254
  7. Cook RJ, Sackett DL. The number needed to treat: A clinically useful measure of treatment effect. BMJ. 1995;310:452–454
  8. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308–315
  9. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383–390
  10. Doctor JN, Slater MA, Atkinson JH. The Descriptor Differential Scale of Pain Intensity: An evaluation of item and scale properties. Pain. 1995;61:251–260
  11. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121
  12. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287–294
  13. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158
  14. Farrar J, Pritchett Y, Robinson M, Watkin J. Clinical importance of changes in pain intensity: An analysis of data from clinical trials of duloxetine in pain disorders [abstract]. J Pain. 2006;4:S39
  15. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol. 1993;20:561–565
  16. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118
  17. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ. 1998;316:690–693
  18. Hanley JA. Receiver operating characteristic (ROC) methodology: The state of the art. Crit Rev Diagn Imaging. 1989;29:307–335
  19. Jenkinson C, Peto V, Coulter A. Measuring change over time: A comparison of results from a global single item of health status and the multi-dimensional SF-36 health status survey questionnaire in patients presenting with menorrhagia. Qual Life Res. 1994;3:317–321
  20. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81–87
  21. Just N, Ciccone DS, Bandilla EB, Wu W. Global impressions versus validated measures of treatment effectiveness in patients with chronic nonmalignant pain. Rehabil Psychol. 1999;44:194–207
  22. Lauridsen HH, Hartvigsen J, Manniche C, Korsholm L, Grunnet-Nilsson N. Responsiveness and minimal clinically important difference for pain and disability instruments in low back pain patients. BMC Musculoskelet Disord. 2006;7:82
  23. NIMH. 1976: ECDEU assessment manual for psychopharmacology, revised 1976. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch. pp 217-222, 313-331
  24. Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, et al. Interpreting change scores for pain and functional status in low back pain: Towards international consensus regarding minimal important change. Spine. 2008;33:90–94
  25. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17:45–56
  26. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–356
  27. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8:283–291
  28. Svensson E. Guidelines to statistical evaluation of data from rating scales and questionnaires. J Rehabil Med. 2001;33:47–48
  29. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27:485–489
  30. Turk DC, Rudy TE, Sorkin BA. Neglected topics in chronic pain treatment outcome studies: Determination of success. Pain. 1993;53:3–16
  31. Vanspall B, Richardson J, Moreland J. Variables for assessing shoulder pain following stroke: A modified Delphi survey. Can J Rehabil. 1996;10:25–34
  32. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411–1420

 This work utilized data from clinical trials sponsored by Eli Lilly and Company, Indianapolis, Indiana.

PII: S1526-5900(09)00588-4

doi: 10.1016/j.jpain.2009.06.007

The Journal of Pain
Volume 11, Issue 2 , Pages 109-118 , February 2010

Article Tools

* Image Usage & Resolution